natgillin/translations-raw huggingface dataset:
In the Grade 2a burn wound study, the mean wound size treated with Episalvan was 108 cm² (range 23-395 cm²). 
Pri študiji ran opeklin stopnje 2a je bila povprečna velikost rane, zdravljene z zdravilom Episalvan, 108 cm² (razpon 23-395 cm²).
Overdosing with Episalvan is unlikely: in patients in which wound sizes >300 cm were repeatedly treated with Episalvan, no betulin plasma levels could be detected. 
Preveliko odmerjanje je pri zdravilu Episalvan malo verjetno: pri bolnikih, pri katerih je velikost rane > 300 cm2 in so bili večkrat zdravljeni z zdravilom Episalvan, v plazmi betulina niso zaznali.
The primary endpoint for the two split-thickness skin graft trials was the intra-individual difference in time to wound closure (at least 95% epithelialisation) based on blinded photo evaluations. 
Primaren cilj pri obeh študijah na ranah na mestu odvzema presadka delne debeline kože je bila intraindividualna razlika pri času do zaprtja rane (vsaj 95-odstotna epitelizacija) na podlagi slepih ocen fotografij.
Since the systemic exposure of Episalvan following cutaneous application is negligible no interaction with systemic treatments is expected. 
Ker je sistemska izpostavljenost zdravilu Episalvan po dermalnem nanosu zanemarljiva, se ne pričakuje medsebojnega delovanja s sistemskimi zdravljenji.
The primary endpoint for the Grade 2a burn wound trial was the percentage of patients with earlier healing (at least 95% epithelialisation) based on blinded photo evaluations. 
Primaren cilj študije na opeklinah stopnje 2a je bil ugotovitev odstotka bolnikov s prejšnjim celjenjem (najmanj 95-odstotna epitelizacija) na podlagi slepega ocenjevanja fotografij.
However, since the amount of Episalvan absorbed into the body is extremely low it is not expected that Episalvan will interact with other medicines. 
Ker pa je količina zdravila Episalvan, ki se absorbira v telo izjemno majhna, se medsebojnega delovanja zdravila Episalvan z drugimi zdravili ne pričakuje.
What you need to know before you use Episalvan 
Kaj morate vedeti, preden boste uporabili zdravilo Episalvan
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 
A. IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z
The active substance was not genotoxic in in vitro assays. 
Zdravilna učinkovina pri preskusih in vitro ni bila genotoksična.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, local tolerance, and phototoxicity. 
Neklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, lokalnega prenašanja in fototoksičnosti ne kažejo posebnega tveganja za človeka.
Episalvan can be used during breast-feeding, unless the chest area is being treated. 
Zdravilo Episalvan se lahko uporablja med dojenjem, razen če se zdravi predel prsnega koša.
Episalvan does not contain birch pollen, so it may be used by people with birch pollen allergy. 
Zdravilo Episalvan ne vsebuje cvetnega praha breze, zato ga ljudje z alergijo na cvetni prah breze lahko uporabljajo.
See section 4.4 and 5.1 with respect to type of wounds studied. 
Za vrste preiskovanih ran glejte poglavji 4.4 in 5.1.
Other wound types 
Druge vrste ran
NAME OF THE MEDICINAL PRODUCT Episalvan gel 
IME ZDRAVILA Episalvan gel
METHOD AND ROUTE(S) OF ADMINISTRATION Cutaneous use. 
POSTOPEK IN POT(I) UPORABE ZDRAVILA dermalna uporaba
Do not use a double dose to make up for a forgotten dose. 
Če ste pozabili uporabiti zdravilo Episalvan Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
Wound infection is a serious complication that can occur during the healing process. 
Okužbe ran so resen zaplet, ki se lahko pojavi med celjenjem rane.
No effects on the breastfed newborn/infant are anticipated since the systemic exposure of the breast-feeding woman to Episalvan is negligible. 
Ni pričakovati vpliva na dojenega novorojenčka/otroka, saj je sistemska izpostavljenost doječe ženske zdravilu Episalvan zanemarljiva.
White collapsible aluminium tube, interior lacquered with epoxy phenolic coating, and with a sealing compound in the fold. 
Bela upogljiva aluminijasta tuba, notranjost prevlečena z epoksifenolno prevleko in tesnilnim sredstvom v ovoju.
75223 Niefern-Öschelbronn GERMANY 
75223 Niefern-Öschelbronn NEMČIJA
75223 Niefern-Öschelbronn Germany 
75223 Niefern-Öschelbronn Nemčija
The gel should be applied to the wound surface at a thickness of approximately 1 mm and covered by sterile wound dressing. 
Gel je treba nanesti na površino rane v debelini približno 1 mm in rano pokriti s sterilnim povojem.
QUALITATIVE AND QUANTITATIVE COMPOSITION 1g gel contains: 100 mg extract (as dry extract, refined) from birch bark from Betula pendula Roth, Betula pubescens Ehrh. 
KAKOVOSTNA IN KOLIČINSKA SESTAVA 1 g gela vsebuje: 100 mg prečiščenega suhega ekstrakta skorje breze vrst Betula pendula Roth in Betula pubescens Ehrh.
Episalvan gel is sterile. 
Episalvan gel je sterilen.
Breast-feeding No data are available to evaluate whether Episalvan is excreted into human milk. 
Ni na voljo podatkov, iz katerih bi ugotovili, ali se zdravilo Episalvan izloča v materino mleko.
No effects on human fertility are anticipated, since the systemic exposure is negligible. 
Ni pričakovati nobenega vpliva na plodnost, saj je sistemska izpostavljenost zanemarljiva.
Duration of use There is no information available on clinical use of Episalvan for more than 4 weeks. 
Trajanje uporabe Podatkov o klinični uporabi zdravila Episalvan, ki presega 4 tedne ni na voljo.
The most frequently reported side effects are: Common side effects (may affect up to 1 in 10 people): - painful skin - itching - complications in the wound healing process 
Pogosti neželeni učinki (prizadenejo lahko največ 1 osebo od 10): - boleča koža - srbenje - zapleti pri celjenju rane
Episalvan gel is administered topically to skin wounds and shows poor absorbtion. 
Zdravilo Episalvan gel se topikalno nanese na kožo in se slabo absorbira.
In the Grade 2a burn wound study an octenidine containing antiseptic wound gel and fatty gauze dressing were used as control. 
Pri študijah na opeklinah stopnje 2a so kot kontrolo uporabili antiseptični gel za rane, ki vsebuje oktinidin, in namaščeno gazo za rane.
Episalvan should be used as advised by your doctor or nurse. 
Če ste prenehali uporabljati zdravilo Episalvan Zdravilo Episalvan uporabljajte, kot vam je svetoval vaš zdravnik ali medicinska sestra.
If necessary, wounds (accidental wounds) should be cleaned according to standard procedure, using e.g. wound antiseptic solution, prior to application of Episalvan. 
Po potrebi je treba rane (rane zaradi nezgod) pred nanosom zdravila Episalvan očistiti po standardnem postopku, tj. z uporabo antiseptične raztopine za rane.
There is no clinical experience from use of Episalvan for the treatment of chronic wounds, e.g. diabetic foot ulcers, venous leg ulcers or wounds in patients with epidermolysis bullosa. 
Kliničnih izkušenj z uporabo zdravila Episalvan, pri zdravljenju kroničnih ran, kot so npr. diabetična stopala, venske razjede na nogah ali rane pri bolnikih z bulozno epidermolizo, ni.
The effect of Episalvan on fertility has not been studied, but since the absorption of this medicine into the body is extremely low, it is not expected to have an effect on your fertility. 
Študij o učinkih zdravila Episalvan na plodnost niso izvedli, ker pa je količina zdravila, ki se absorbira v telo izjemno majhna, se ne pričakuje, da zdravilo vpliva na plodnost.
Warnings and precautions Talk to your doctor or nurse before using Episalvan. 
Opozorila in previdnostni ukrepi Pred začetkom uporabe zdravila Episalvan se posvetujte z zdravnikom.
LIST OF EXCIPIENTS Excipient: Sunflower oil. 
SEZNAM POMOŽNIH SNOVI Pomožna snov: sončnično olje.
There is no experience from long-term use of Episalvan for more than 4 weeks. 
Ni izkušenj z dolgotrajno uporabo zdravila Episalvan, ki presega 4 tedne.
No studies have been done on the effects of Episalvan on pregnant women, but since the absorption of this medicine into the body is extremely low, the risk to the unborn baby is negligible. 
Študij o učinkih zdravila Episalvan na nosečnice niso izvedli, ker pa je količina zdravila, ki se absorbira v telo izjemno majhna, je tveganje za nerojenega otroka zanemarljivo.
If your wound shows no signs of improvement over time, talk to your doctor or nurse. 
Če se stanje vaše rane ne sčasoma ne izboljša, se pogovorite s svojim zdravnikom ali medicinsko sestro.
See section 4.4 with respect to wound size and duration of treatment. 
Za velikost rane in trajanje zdravljenja glejte poglavje 4.4.
How to store Episalvan 6. 
Shranjevanje zdravila Episalvan 6.
This product is for single use only and once opened, the product should be used immediately. 
To zdravilo je za enkratno uporabo in ga morate uporabiti nemudoma po odprtju.
In the burn wound study with 61 patients, the mean study wound area was 216 cm2; the total burn injury of these patients was larger and affected 5.8% of the total body surface area. 
2; celotne opekline teh bolnikov so bile večje in so prizadele 5,8 % študijo, 216 cm celotne površine telesa.
For a subset of patients blinded photo-evaluation indicated better results for Episalvan treated wound halves compared to standard of care in pigmentation, redness and texture of the former wound areas. 
Za podskupino bolnikov je slepo ocenjevanje fotografij glede pigmentacije, pordelosti in teksture območji ran pokazalo boljše rezultate pri polovicah ran, zdravljenih z zdravilom Episalvan, v primerjavi s polovicami ran, zdravljenimi s standardno oskrbo.
Driving and using machines Your ability to drive and use machines will not be affected by this medicine. 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo ne vpliva na vašo sposobnost upravljanja vozil in strojev.
How to use Episalvan 
Kako uporabljati zdravilo Episalvan
75223 Niefern-Öschelbronn Germany tel +49 (0) 7233 9749 - 0 fax+49 (0) 7233 9749 - 210 
Faks: +49 (0) 7233 9749 - 210
The mean wound size treated with Episalvan in clinical studies in split-thickness skin graft donor site wounds was 40.7 cm² (range 8-300 cm²). 
V kliničnih študijah na ranah na mestu odvzema kožnega presadka delne debeline kože je bila povprečna velikost rane, zdravljene z zdravilom Episalvan, 40,7 cm² (razpon 8300 cm²).
Application was at each wound dressing change every third to fourth day until full wound closure up to 28 days for the splitthickness skin graft trials, and every other day up to 21 days for the Grade 2a burn trial. 
Pri študijah na ranah na mestu odvzema presadka delne debeline kože so nanos opravili ob vsakem previjanju rane, vsake tri do štiri dni, do popolnega zaprtja rane ali do 28 dni, pri študiji na opeklinah stopnje 2a pa vsak drug dan do 21 dni.
There is no experience of the use of Episalvan for the treatment of chronic wounds, e.g. diabetic foot ulcers or venous leg ulcers. 
Za uporabo zdravila Episalvan ni izkušenj pri zdravljenju kroničnih ran, npr. diabetičnih stopal ali venskih razjed na nogah.
• If necessary, wounds should be cleansed using a suitable antiseptic solution prior to application of Episalvan 
• Po potrebi se rane pred nanosom zdravila Episalvan očisti s primerno antiseptično raztopino.
• Episalvan should be applied to the wound surface at a thickness of approximately 1 mm and covered by a sterile wound dressing. 
• Zdravilo Episalvan nanesite na površino rane v debelini približno 1 mm in rano pokrijte s sterilnim povojem.
No studies have been performed to establish whether Episalvan will interact with other medicines. 
Študij za ugotovitev medsebojnega delovanja zdravila Episalvan z drugimi zdravili niso izvedli.
No effects during pregnancy are anticipated, since systemic exposure to Episalvan is negligible. 
Med nosečnostjo ni pričakovati nobenega vpliva, saj je sistemska izpostavljenost zanemarljiva.
1 g gel contains: 100 mg extract (as dry extract, refined) from birch bark from Betula pendula, Betula pubescens as well as hybrids of both species (equivalent to 0.5-1.0 g birch bark), corresponding to 72-88 mg betulin. 
1 g gela vsebuje: 100 mg prečiščenega suhega ekstrakta skorje breze vrst Betula pendula in Betula pubescens ter tudi iz hibridov obeh vrst (enakovrednega 0,5-1,0 g skorje breze), kar ustreza 72-88 mg betulina.
Episalvan gel Birch bark extract 
Episalvan gel ekstrakt skorje breze
No formal studies have been conducted with Episalvan in patients with renal or hepatic impairment. 
Pri bolnikih z okvaro ledvic ali jeter niso izvedli nobene uradne študije z zdravilom Episalvan.
STATEMENT OF ACTIVE SUBSTANCE(S) 1g gel contains: 100 mg birch bark extract (as dry extract, refined) from Betula pendula/Betula pubescens, corresponding to 72-88 mg betulin. 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN 1 g gela vsebuje: 100 mg ekstrakta skorje breze (v obliki suhega ekstrakta, rafiniranega) iz vrst Betula pendula/Betula pubescens, kar ustreza 72-88 mg betulina.
Birch pollen allergy 
Alergija na cvetni prah breze
Discard after use. 
Po uporabi zavrzite.
Fresh wounds should achieve haemostasis prior to application of Episalvan. 
Pred uporabo zdravila Episalvan morajo sveže rane doseči popolno hemostazo.
- If you get any side effects, talk to your doctor or nurse. 
- Če opazite kateri koli neželeni učinek, se posvetujte s svojim zdravnikom ali medicinsko sestro.
Episalvan plus wound dressing was applied to half of the wound area, and the same kind of non-adhesive wound dressing alone was applied to the other half as the control in the split-thickness skin graft donor site studies. 
Pri ranah na mestu odvzema presadka delne debeline kože so na polovico območja rane nanesli zdravilo Episalvan in ga povili s povojem, na drugo polovico rane pa so kontrolno namestili samo nelepljiv povoj.
Partial thickness burn wounds 
Opekline delne debeline kože
The tubes are closed with a tamper-evident aluminium membrane and fitted with a white polypropylene screw cap. 
Tube so zaprte z aluminijasto membrano, ki je ni mogoče odpreti brez vidnih poškodb, in opremljene s polipropilensko zaporko.
If you get any side effects, talk to your doctor or nurse. 
Če opazite kateri koli neželeni učinek, se posvetujte s svojim zdravnikom ali medicinsko sestro.
For cutaneous application. 
Za dermalno uporabo.
Adverse reactions were administration site reactions only. 
Neželeni učinki so bili omejeni zgolj na mesto nanosa.
-1.0 days (CI: -1.4, -0.6) faster wound closure with Episalvan, p<0.0001a 
-1,0 dneva (CI: -1,4,0,6) hitrejše zapiranje rane z zdravilom Episalvan, p < 0,0001a a Na podlagi dvostranskega parnega t-testa.
BATCH NUMBER Lot 
ŠTEVILKA SERIJE Številka serije
Infections and infestations 
Infekcijske in parazitske bolezni okužbe ran
The 219 patients with split-thickness skin graft donor site wounds had a mean age of 53 years; their donor site mean wound size was 81.5 cm2. 
Pri študiji povprečna starost 53 let; povprečna velikost mesta odvzema je bila 81,5 cm opeklin z 61 bolniki je bila povprečna velikost rane, pri bolnikih, ki so bili vključeni v
OUTER CARTON and TUBE 
PODATKI NA ZUNANJI OVOJNINI IN PRIMARNI OVOJNINI ŠKATLA in TUBA
How to store Episalvan 
Shranjevanje zdravila Episalvan
No data have been generated to study the effect of accidental ingestion of Episalvan. 
Proučevanje učinka naključnega zaužitja zdravila Episalvan ni možno, ker ni podatkov.
This summary was last updated in September 2011. 
Povzetek je bil nazadnje posodobljen septembra 2011.
The vaccine was generally well tolerated and shown to be safe. 
Cepivo so živali na splošno dobro prenašale in izkazalo se je kot varno.
The vaccine is given just behind the ear. 
Cepivo se daje za uho.
To maintain the immunity, a single injection of one dose should be carried out 2 - 4 weeks before each subsequent farrowing. 
Za ohranjanje imunosti je potrebna ena injekcija z enojnim odmerkom 2 do 4 tedne pred vsako naslednjo prasitvijo.
The withdrawal period is the time allowed after administration of the medicine before the animal can be slaughtered and the meat used for human consumption. 
Obdobje karence je čas, ki mora preteči po uporabi zdravila, preden se lahko žival zakolje in meso uporabi za prehrano ljudi.
The vaccine is given to sows (female pigs) only. 
Cepivo se daje le svinjam (samicam).
In the study of the duration of effect, based on antibody levels, it was shown that revaccination with a single dose resulted in a clear booster response (that is, the resultant antibody levels were even higher than after the basic vaccination). 
V okviru študije trajanja učinka, ki je izhajala iz ravni protiteles, je bilo dokazano, da je ponovno cepljenje z enojnim odmerkom povzročilo okrepljeni odziv (to pomeni, da so bile nato ravni protiteles celo višje kot po prvem cepljenju).
When the sow is injected, this small exposure helps the pig's immune system to recognise and attack the bacteria. 
Ko svinja prejme cepivo, ta majhna izpostavitev pripomore, da njen imunski sistem prepozna in napade bakterijo.
When exposed to any of these bacteria later in life, the pig will either not become infected or have a much less serious infection. 
Če bo prašič pozneje izpostavljen tem sevom, se ne bo okužil oziroma bo okužba bistveno blažja.
This bacterium is often present with Pasteurella multocida and makes the disease worse. 
Ta bakterija se pogosto pojavlja skupaj z bakterijo Pasteurella multocida in otežuje bolezen.
Other side effects are reduced activity and lack of appetite in 10-20% of the pigs on the day of vaccination and/or a temporary swelling (maximum diameter: 10 cm) for up to two weeks at the injection site. 
Drugi neželeni učinki sta zmanjšana aktivnost in tek pri 10 do 20 % prašičev na dan cepljenja in/ali prehodna oteklina na mestu injiciranja (največjega premera: 10 cm), ki traja do dveh tednov.
If someone is accidentally injected with this product, they should seek immediate medical advice immediately. 
Ob nenamernem vbrizganju tega zdravila je treba takoj poiskati zdravniško pomoč.
Porcilis AR-T DF can cause a temporary increase in body temperature of 1.5°C, and in some pigs of up to 3°C on the day of vaccination or the following day. 
Zdravilo Porcilis AR-T DF lahko povzroči prehodno povišanje telesne temperature za 1,5 °C, pri nekaterih prašičih pa tudi za do 3 °C na dan cepljenja ali naslednji dan.
The first injection should be given 6 weeks before the expected date of farrowing (giving birth to the piglets). 
Prvo injekcijo je treba dati 6 tednov pred pričakovano prasitvijo (skotitvijo pujskov).
The first dose is followed by a second injection 4 weeks later. 
Prvemu odmerku po 4 tednih sledi drugi.
The European Commission granted a marketing authorisation valid throughout the European Union for Porcilis AR-T DF to Intervet International B.V. on 16 November 2000. 
Evropska komisija je dovoljenje za promet z zdravilom Porcilis AR-T DF, veljavno po vsej Evropski uniji, odobrila družbi Intervet International B.V.
The withdrawal period for Porcilis AR-T DF for pigs is zero days. 
Obdobje karence za zdravilo Porcilis AR-T DF za prašiče je nič dni.
The trials showed good protection against the clinical signs of progressive atrophic rhinitis. 
Študije so pokazale dobro zaščito proti kliničnim znakom progresivnega atrofičnega rinitisa.
The piglets had comparable levels of antibodies against progressive atrophic rhinitis as obtained with another approved vaccine. 
Pujski so imeli primerljive ravni protiteles proti progresivnemu atrofičnemu rinitisu, kot so bile dosežene z drugim odobrenim cepivom.
The Pasteurella multocida toxin is made by a bacterium cell that has received a gene (DNA), which makes it able to produce Pasteurella multocida toxoid, a genetically modified form of toxin which has adequate immunogenic activity and which is free from the toxic properties. 
Toksin Pasteurella multocida proizvaja celica bakterije, ki je prejela gen (DNK), ki ji omogoča tvorjenje toksoida Pasteurella multocida, genetsko modificirane oblike toksina, ki ima zadostno imunogenost, vendar pa nima toksičnih lastnosti.
An active ingredient of Porcilis AR-T DF, Pasteurella multocida toxin, is produced by a method known as ‘recombinant technology'. 
Zdravilna učinkovina zdravila Porcilis AR-T DF, toksin Pasteurella multocida, se proizvaja z metodo, imenovano rekombinantna tehnologija.
The Package Leaflet should be taken to the doctor. 
Zdravniku je treba pokazati navodilo za uporabo zdravila.
The main measure of effectiveness was the amount of antibodies to Bordetella bronchiseptica and also to Pasteurella multocida toxin. 
Glavno merilo učinkovitosti je bila količina protiteles, ki se tvorijo zoper bakterijo Bordetella bronchiseptica in tudi zoper toksin bakterije Pasteurella multocida.
of the Pasteurella multocida toxin and inactivated Bordetella bronchiseptica cells. 
toksina Pasteurella multocida in inaktiviranih celic Bordetella bronchiseptica.
Porcilis AR-T DF is a suspension for injection which contains a non-toxic recombinant derivative (see ‘How does Porcilis AR-T DF work?') 
Zdravilo Porcilis AR-T DF je suspenzija za injiciranje, ki vsebuje netoksični rekombinantni derivat (glej „Kako zdravilo Porcilis AR-T DF deluje? )
What benefit has Porcilis AR-T DF shown during the studies? 
Kakšne koristi je zdravilo Porcilis AR-T DF izkazalo med študijami?
Other information about Porcilis AR-T DF: 
Druge informacije o zdravilu Porcilis AR-T DF:
The Committee for Medicinal Products for Veterinary Use (CVMP) agreed that the benefits of Porcilis AR-T DF exceed the risks for the reduction of clinical signs of progressive atrophic rhinitis in piglets, by passive oral immunisation with colostrum from dams actively immunised with the vaccine, and recommended that Porcilis AR-T DF should be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Porcilis AR-T DF za zmanjšanje kliničnih znakov progresivnega atrofičnega rinitisa pri pujskih s pasivno peroralno imunizacijo s kolostrumom samic, ki so bile aktivno imunizirane s cepivom, večje od z njim povezanih tveganj in priporočil, da se zanj odobri dovoljenje za promet.
In this study, blood was taken from piglets in each litter born from each sow, and tested for antibodies to Pasteurella multocida toxin and Bordetella bronchiseptica. 
V tej študiji so pujskom iz vsakega legla vsake svinje odvzeli kri in testirali raven protiteles zoper toksin bakterije Pasteurella multocida in bakterijo Bordetella bronchiseptica.
Porcilis AR-T DF contains a non-toxic recombinant derivative (see later) of the Pasteurella multocida toxin and also inactivated Bordetella bronchiseptica bacterial cells. 
Zdravilo Porcilis AR-T DF vsebuje netoksični rekombinantni derivat (glej spodaj) toksina bakterije Pasteurella multocida in tudi inaktivirane celice bakterije Bordetella bronchiseptica.
Porcilis AR-T DF is used to reduce the clinical signs of progressive atrophic rhinitis (a disease where the nose tissues become infected and die) in piglets. 
Zdravilo Porcilis AR-T DF se uporablja za zmanjšanje kliničnih znakov progresivnega atrofičnega rinitisa (bolezni, pri kateri pride do okužbe nosnih tkiv, ki nato odmrejo) pri pujskih.
Progressive atrophic rhinitis is caused by toxins from the bacteria Pasteurella multocida. 
Progresivni atrofični rinitis povzročajo toksini bakterije Pasteurella multocida.
Vaccine to reduce atrophic rhinitis in piglets 
Cepivo za ublažitev atrofičnega rinitisa pri pujskih
What is the risk associated with Porcilis AR-T DF? 
Kakšna tveganja so povezana z zdravilom Porcilis AR-T DF?
Why has Porcilis AR-T DF been approved? 
Zakaj je bilo zdravilo Porcilis AR-T DF odobreno?
This immunity is passed onto the sow's piglets through her colostrum. 
Imunost se prek kolostruma prenaša s svinje na pujske.
Porcilis AR-T DF has been studied in sows, where it was compared with another vaccine for progressive atrophic rhinitis. 
Zdravilo Porcilis AR-T DF so preučevali pri svinjah in ga primerjali z drugim cepivom za progresivni atrofični rinitis.